Template:SUIT-001: Difference between revisions

From Bioblast
No edit summary
No edit summary
Line 24: Line 24:
| PM<sub>''P''</sub> or PM_P: N-OXPHOS capacity, N<sub>''P''</sub>  
| PM<sub>''P''</sub> or PM_P: N-OXPHOS capacity, N<sub>''P''</sub>  


OXPHOS capacity, ''P'' (with saturating [ADP]), with NADH-linked substrates.
{{Template:SUIT N}} {{Template:SUIT OXPHOS}}


|-
|-
Line 33: Line 33:
| PMc<sub>''P''</sub> or PMc_P: Cytochrome c test for quality control
| PMc<sub>''P''</sub> or PMc_P: Cytochrome c test for quality control


Addition of cytochrome ''c'' yields a test for integrity of the [[mtOM]]. Stimulation by added cytochrome ''c'' would indicate an injury of the mtOM and limitation of respiration in state N<sub>''P''</sub> due to loss of cytochrome ''c'' (''P'', OXPHOS capacity with type N substrates). Cytochrome ''c'' is added immediately after the earliest ADP-activation step.
{{Template:SUIT N}} {{Template:SUIT OXPHOS}} {{Template:SUIT c}}


|-
|-
Line 42: Line 42:
| PM<sub>''E''</sub> or PM_E: N-ET capacity, N<sub>''E''</sub>
| PM<sub>''E''</sub> or PM_E: N-ET capacity, N<sub>''E''</sub>


Uncoupler titration (avoiding inhibition by high uncoupler concentrations) to obtain electron transfer (ET) capacity (noncoupled ET-state), as a test for limitation of OXPHOS-capacity by the phosphorylation system (ANT, ATP synthase, phosphate transporter) relative to ET-capacity, E.
{{Template:SUIT N}} {{Template:SUIT U*}}


|-
|-
Line 49: Line 49:
| [[N]]
| [[N]]
| CI
| CI
| PGM<sub>''E''</sub> or PGM_E: N-ET capacity, N<sub>''E''</sub>
{{Template:SUIT N}} {{Template:SUIT ET}}


|-
|-
Line 55: Line 58:
| [[NS]]
| [[NS]]
| CI&II
| CI&II
| GMS<sub>''P''</sub> or GMS_P: NS-OXPHOS capacity, NS<sub>''P''</sub>
| GMS<sub>''E''</sub> or GMS_E: NS-OXPHOS capacity, NS<sub>''E''</sub>


Respiratory stimulation by further addition of succinate, S, to type N substrates, with convergent electron flow in the NS-pathway (CI<small>&</small>II-linked pathway to the Q-junction) for reconstitution of TCA cycle function, in the coupled state as an estimate of OXPHOS-capacity, ''P''.
{{Template:SUIT N}} & {{Template:SUIT S}} {{Template:SUIT NS}} {{Template:SUIT ET}}


|-
|-
| 6Oct
| 6Oct
| [[OctPGMS]](E)
| [[OctPGMS]]<sub>''E''</sub>
| [[FNS]]
| [[FNS]]
| FAO&CI&II
| FAO&CI&II
| OctGMS<sub>''P''</sub> or GMS_P: NS-OXPHOS capacity, NS<sub>''P''</sub>
{{Template:SUIT FNS}} {{Template:SUIT ET}}


|-
|-
Line 72: Line 78:
| S<sub>''E''</sub> or S_E: S-ET capacity
| S<sub>''E''</sub> or S_E: S-ET capacity


S-pathway ET-capacity after blocking CI with rotenone, inhibiting the N- and F-pathways.
{{Template:SUIT Rot}} {{Template:SUIT ET}}


|-
|-
Line 79: Line 85:
| [[SGp]]
| [[SGp]]
| CII&GpDH
| CII&GpDH
| SGp<sub>''E''</sub> or SGp_E: SGp-ET capacity
{{Template:SUIT SGp}} {{Template:SUIT ET}}


|-
|-
Line 87: Line 96:
| ROX: residual oxygen consumption
| ROX: residual oxygen consumption


''Rox'' is due to oxidative side reactions, estimated after addition of Antimycin A (inhibitor of CIII). ''Rox'' is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).
{{Template:SUIT Ama}}


|}
|}


{{Template:SUIT CIV}}
{{Template:SUIT CIV}}

Revision as of 14:08, 11 January 2019

SUIT-001

Step Respiratory state Pathway control ET-Complex entry into Q-junction Comment
1PM PML N CI PML or PM_L: Pyruvate & Malate, N-LEAK respiration, NL

NADH-linked substrates (type N-pathway to Q). Template:SUIT L n

2D PMP N CI PMP or PM_P: N-OXPHOS capacity, NP

NADH-linked substrates (type N-pathway to Q). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state.

2c PMcP N CI PMcP or PMc_P: Cytochrome c test for quality control

NADH-linked substrates (type N-pathway to Q). OXPHOS capacity P (with saturating [ADP]), active OXPHOS state. Addition of cytochrome c yields a test for integrity of the mtOM (cytochrome c control efficiency). Stimulation by added cytochrome c would indicate an injury of the mtOM and limitation of respiration in the preceding state without added c due to loss of cytochrome c. Typically, cytochrome c is added immediately after the earliest ADP-activation step (OXPHOS capacity P with saturating [ADP]).

3U PME N CI PME or PM_E: N-ET capacity, NE

NADH-linked substrates (type N-pathway to Q). Uncoupler titration (avoiding inhibition by high uncoupler concentrations) to obtain electron transfer (ET) capacity E (noncoupled ET-state). Test for limitation of OXPHOS capacity P by the phosphorylation system (ANT, ATP synthase, phosphate transporter) relative to ET capacity E in mt-preparations: E-P control efficiency and E-L coupling efficiency. In living cells: E-R control efficiency and E-L coupling efficiency.

4G PGM(E) N CI PGME or PGM_E: N-ET capacity, NE

NADH-linked substrates (type N-pathway to Q). Noncoupled electron transfer state, ET state, with ET capacity E.

5S PGMSE NS CI&II GMSE or GMS_E: NS-OXPHOS capacity, NSE

NADH-linked substrates (type N-pathway to Q). & Succinate, S ( type S-pathway to Q). Respiratory stimulation by simultaneous action of type N substrates & succinate, with convergent electron flow in the NS-pathway for reconstitution of TCA cycle function. Noncoupled electron transfer state, ET state, with ET capacity E.

6Oct OctPGMSE FNS FAO&CI&II OctGMSP or GMS_P: NS-OXPHOS capacity, NSP

Respiratory stimulation by simultaneous action of the F-pathway, N-pathway, and S-pathway, with convergent electron flow in the FNS-pathway for reconstitution of TCA cycle function and additive or inhibitory effect of F. Noncoupled electron transfer state, ET state, with ET capacity E.

7Rot SE S CII SE or S_E: S-ET capacity

Succinate pathway control state (S-pathway) after inhibiting CI with rotenone, which also inhibits the F-pathway. Noncoupled electron transfer state, ET state, with ET capacity E.

8Gp SGp(E) SGp CII&GpDH SGpE or SGp_E: SGp-ET capacity

Respiratory stimulation by action of succinate and glycerophosphate, Gp, with convergent electron flow in the SGp-pathway (CII&GpDH-linked pathway to the Q-junction). Noncoupled electron transfer state, ET state, with ET capacity E.

9Ama ROX ROX: residual oxygen consumption

Rox is the residual oxygen consumption in the ROX state, due to oxidative side reactions, estimated after addition of antimycin A (inhibitor of CIII). Rox is subtracted from oxygen flux as a baseline for all respiratory states, to obtain mitochondrial respiration (mt).

Step Respiratory state Pathway control ET-Complex Comment
## AsTm AsTmE CIV CIV
## Azd CHB
Cookies help us deliver our services. By using our services, you agree to our use of cookies.